研究所

トップページ研究所研究分野紹介腫瘍制御学分野業績

腫瘍制御学分野 業績

【代表的な原著論文】（* corresponding author）

  1. Dong Y, Yoshida T, Maeda M, Adachi H, Eguchi A, Mishiro-Sato E, Okuzaki D, Kataoka Y, Yoshida T, *Oneyama C. Stress granules as RNA triage hubs suppress extracellular vesicle secretion under oxidative stress in cancer. Proc Natl Acad Sci USA, 2026;123:e25339901
  2. Adachi H, Yoshida T, Itoh R, *Oneyama C. Ouabain suppresses CD63 loading into extracellular vesicles via Na⁺/K⁺-ATPase-dependent localization to autophagosomes. Biol Pharm Bull, 2025;49:291-300
  3. Kunitake K, Mizuno T, Hattori K, Oneyama C, Kamiya M, Ota S, Urano Y, Kojima R. Barcoding of small extracellular vesicles with CRISPR-gRNA enables comprehensive, subpopulation-specific analysis of their biogenesis/release regulators. Nat Commun. 15(1), 9777 (2024)
  4. Hayasaka R, Tabata S, Hasebe M, Ikeda S, Hikita T, Oneyama C, Yoshitake J, Onoshima D, Takahashi K, Shibata T, Uchida K, Baba Y, Soga T, Tomita M, Hirayama A, Metabolomics of small extracellular vesicles derived from isocitrate dehydrogenase 1-mutant HCT116 cells collected by semi-automated size exclusion chromatography. Front Mol Biosci., 9, 1049402 (2023)
  5. Mitani F, Hayasaka R, Hirayama A, *Oneyama C. SNAP23-Mediated Perturbation of Cholesterol-Enriched Membrane Microdomain Promotes Extracellular Vesicle Production in Src-Activated Cancer Cells. Biol Pharm Bull. 45(10):1572-1580, 2022. (PMID: 36184518) 
  6. Hikita T, *Oneyama C. Quantification and Imaging of Exosomes via Luciferase-Fused Exosome Marker Proteins: ExoLuc System. Methods Mol Biol. 2524:281-290, 2022. (PMID: 35821479)
  7. Mitani F, Lin J, Sakamoto T, Uehara R, Hikita T, Yoshida T, Setiawan A, Arai M, *Oneyama C. Asteltoxin inhibits extracellular vesicle production through AMPK/mTOR-mediated activation of lysosome function. Sci Rep. 12(1):6674, 2022. (PMID: 35461323) 
  8. Hikita T, Uehara R, Itoh RE, Mitani F, Miyata M, Yoshida T, Yamaguchi R, *Oneyama C. MEK/ERK-mediated oncogenic signals promote secretion of extracellular vesicles by controlling lysosome function. Cancer Sci. 113(4):1264-1276, 2022. (PMID: 35108425)
  9. Morioka S, Nakanishi H, Yamamoto T, Hasegawa J, Tokuda E, Hikita T, Sakihara T, Kugii Y, Oneyama C, Yamazaki M, Suzuki A, Sasaki J, Sasaki T. A mass spectrometric method for in-depth profiling of phosphoinositide regioisomers and their diseaseassociated regulation. Nat Commun. 13(1):83, 2022. (PMID: 35013169) 
  10. Kunou S, Shimada K, Takai M, Sakamoto A, Aoki T, Hikita T, Kagaya Y, Iwamoto E, Sanada M, Shimada S, Hayakawa F, Oneyama C, Kiyoi H. Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma. Oncogene, 40(23):3989-4003, 2021. (PMID: 33994542)
  11. Ito RE, Oneyama C, Aoki K. Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction. PLoS One, 16(4): e0249388, 2021. (PMID: 33793658) 
  12. Nishimura T, Oyama T, Hu HT, Fujioka T, Hanawa-Suetsugu K, Ikeda K, Yamada S, Kawana H, Saigusa D, Ikeda H, Kurata R, Oono-Yakura K, Kitamata M, Kida K, Hikita T, Mizutani K, Yasuhara K, Mimori-Kiyosue Y, Oneyama C, Kurimoto K, Hosokawa Y, Aoki J, Takai Y, Arita M, Suetsugu S. Filopodium-derived vesicles produced by MIM enhance the migration of recipient cells. Dev Cell, 56(6), 842-859, 2021. (PMID: 33756122)
  13. Hikita T, Miyata M, Watanabe R, *Oneyama C. In vivo imaging of long-term accumulation of cancer-derived exosomes using a BRET-based reporter. Sci Rep, 10(1): 16616, 2020. (PMID: 33024173)
  14. Watanabe R, Miyata M, *Oneyama C. Rictor promotes tumor progression of rapamycin-insensitive triple-negative breast cancer cells. Biochem Biophys Res Commun, 531(4), 636-642, 2020. (PMID: 32819718)
  15. Okuzaki D, Yamauchi T, Mitani F, Miyata M, Ninomiya Y, Watanabe R, Akamatsu H, *Oneyama C. c-Src promotes tumor progression through downregulation of microRNA-129-1-3p. Cancer Sci. 111(2), 418-428, 2020. (PMID: 31799727)
  16. Hikita T, Kuwahara A, Watanabe R, Miyata M, *Oneyama C. Src in endosomal membranes promotes exosome secretion and tumor progression. Sci Rep, 9(1), 3265, 2019. (PMID: 30824759)
  17. Hikita T, Miyata M, Watanabe R, *Oneyama C. Sensitive and rapid quantification of exosomes by fusing luciferase to exosome marker proteins. Sci Rep, 8(1), 14035, 2018. (PMID: 30232365)
  18. Kokuda R, Watanabe R, Okuzaki D, Akamatsu H, *Oneyama C. MicroRNA-137-mediated Src oncogenic signaling promotes cancer progression. Genes Cells, 23(8), 688-701, 2018. (PMID: 29962093)
  19. *Oneyama C, Yoshikawa Y, Ninomiya Y, Iino T, Tsukita S, Okada M. Fer tyrosine kinase oligomer mediates and amplifies Src-induced tumor progression. Oncogene, 35(4), 501-512, 2016. (PMID: 25867068)
  20. Matsuyama R, Okuzaki D, Okada M, *Oneyama C.: miR-27b suppresses tumor progression by regulating ARFGEF1 and the focal adhesion signaling. Cancer Science, 107(1): 28-35, 2016. (PMID: 26473412)
  21. Kakumoto K, Ikeda J, Okada M, Morii E, *Oneyama C.: mLST8 promotes mTOR-mediated tumor progression. PLoS One, 10(4): e0119015, 2015. (PMID: 25906254)
  22. Kajiwara K, Yamada T, Bamba T, Fukusaki E, Imamoto F, Okada M, *Oneyama C.: c-Src-induced activation of ceramide metabolism impairs membrane microdomains and promotes malignant progression by facilitating the translocation of c-Src to focal adhesions. Biochem J, 458(1): 81-93, 2014. (PMID: 24266736)
  23. *Oneyama C, Kito Y, Asai R, Ikeda J, Yoshida T, Okuzaki D, Kokuda R, Kakumoto K, Takayama K, Inoue S, Morii E, Okada M.: MiR-424/503-mediated Rictor upregulation promotes tumor progression. PLoS One, 8(11): e80300, 2013. (PMID: 24244675)
  24. *Oneyama C, Morii E, Okuzaki D, Takahashi Y, Ikeda J, Wakabayashi N, Akamatsu H, Tsujimoto M, Nishida T, Aozasa K, Okada M.: MicroRNA-mediated upregulation of integrin-linked kinase is crucial for Src-induced tumor progression. Oncogene, 31(13), 1623-1635, 2012. (PMID: 21860426)
  25. *Oneyama C, Ikeda J, Okuzaki D, Suzuki K, Kanou T, Shintani Y, Morii E, Okumura M, Aozasa K, Okada M.: MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene, 30(32): 3489-3501, 2011. (PMID: 21383697)
  26. Kuroiwa M, Oneyama C, Nada S, Okada M.: The guanine nucleotide exchange factor Arhgef5 plays crucial roles in c-Src-induced podosome formation. J Cell Sci, 124: 1726-1738, 2011. (PMID: 21525037)
  27. Suzuki K, Oneyama C, Kimura H, Tajima S, Okada M.: Downregulation of the tumor suppressor Cbp/PAG1 is mediated by epigenetic histone modifications via the MAPK/PI3K pathway. J Biol Chem, 286(18): 15698-15706, 2011. (PMID: 21388951)
  28. Kanou T, Oneyama C, Kawahara K, Okimura A, Ohta M, Ikeda N, Shintani Y, Okumura M, Okada M.: The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation. Mol Cancer Res, 9(1): 103-114, 2011. (PMID: 21156787)
  29. Hikita T, Oneyama C, Okada M.: Purvalanol A, a CDK inhibitor, effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src. Genes Cells, 15(10): 1051-1062, 2010. (PMID: 20825494)
  30. Oneyama C, Iino T, Saito K, Suzuki K, Ogawa A, Okada M.: Transforming potential of Src family kinases is limited by the cholesterol-enriched membrane microdomain. Mol Cell Biol, 29(24): 6462-6472, 2009. (PMID: 19822664)
  31. Inoue K, Sone T, Oneyama C, Nishiumi F, Kishine H, Sasaki Y, Andoh T, Okada M, Chesnut JD, Imamoto F.: A versatile nonviral vector system for tetracycline-dependent one-step conditional induction of transgene expression. Gene Therapy, 16(12): 1383-1394, 2009. (PMID: 19759563)
  32. Oneyama C, Hikita T, Enya K, Dobenecker MW, Saito K, Nada S, Tarakhovsky A, Okada M. : The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src. Mol Cell, 30(4): 426-436, 2008. (PMID: 18498747)
  33. Saito K, Enya K, Oneyama C, Hikita T, Okada M.: Proteomic identification of ZO-1/2 as a novel scaffold for Src/Csk regulatory circuit. Biochem Biophys Res Commun, 366(4): 969-975, 2008. (PMID: 18086565)
  34. Oneyama C, Hikita T, Nada S, Okada M.: Functional dissection of transformation by c-Src and v-Src. Genes Cells, 13(1): 1-12, 2008. (PMID: 18173743)
  35. Yagi R, Waguri S, Sumikawa Y, Nada S, Oneyama C, Itami S, Schmedt C, Uchiyama Y, Okada M.: C-terminal Src kinase controls development and maintenance of mouse squamous epithelia. EMBO J, 26(5): 1234-1244, 2007. (PMID: 17304209)
  36. Sukezane T, Oneyama C, Kakumoto K, Shibutani K, Hanafusa H and Akagi T.: Human diploid fibroblasts are resistant to MEK/ERK-mediated disruption of the actin cytoskeleton and invasiveness stimulated by Ras. Oncogene, 24: 5648-5655, 2005. (PMID: 16007212)
  37. Oneyama C, Agatsuma T, Kanda Y, Nakano H, Sharma SV, Nakano H, Narazaki F and Tatsuta K.: Synthetic Inhibitors of Proline-Rich Ligand-Mediated Protein-Protein Interaction: Potent Analogs of UCS15A. Chemistry & Biology, 10: 443-451, 2003. (PMID: 12770826)
  38. Oneyama C, Nakano H and Sharma SV.: UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug. Oncogene, 21: 2037-2050, 2002. (PMID: 11960376)
  39. Sharma SV, Oneyama C, Yamashita Y, Nakano H, Sugawara K, Hamada M, Kosaka N and Tamaoki T.: UCS15A, a non-kinase inhibitor of Src signal transduction. Oncogene, 20: 2068-2079, 2001. (PMID: 11360191)

総説など

  1. 小根山千歳：「がんシグナルによる細胞外小胞の分泌亢進メカニズム」実験医学増刊号「EVs 細胞外小胞の生物学」39(20), 3141-3147, 2021
  2. 小根山千歳：「チロシンキナーゼ：分子標的薬を極める―基礎から臨床まで―」産科と婦人科,、診断と治療社、87(10), 1150-1155, 2020
  3. 小根山千歳ら：「脂質ラフトによるSrcの空間的制御とがん進展」実験医学増刊号「知る・見る・活かす！シグナリング研究2015」33(10):82-87, 羊土社（2015）
  4. Oneyama C. et al. : MicroRNAs as the fine-tuners of Src oncogenic signaling. J Biochem, 157(6): 431-438, 2015. （PMID: 25862810）
  5. 小根山千歳：「Srcがん形質におけるmicroRNA異常とmTORシグナル」次世代がん戦略研究update がん基盤生物学－革新的シーズ育成に向けて－, 248-253, 南山堂（2013）
  6. 小根山千歳ら：「細胞膜ミクロドメイン”ラフト”を介するSrcがん化シグナル制御機構」蛋白質核酸酵素、54(3): 201-211, 共立出版（2009）
  7. 小根山千歳ら：「チロシンキナーゼシグナルとがん形質発現」実験医学増刊号「シグナル伝達2008-2009」26(15): 41-48, 羊土社（2008）